AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $192.00. The ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report)’s stock price gapped up before the market opened on Monday after HC Wainwright raised their price target on the stock from $90.00 to $ ...

SAN DIEGO—Matthew Singleton, a director at Viking Therapeutics, Inc. (NASDAQ:VKTX), recently executed a significant stock sale, according to a filing with the Securities and... ByInvesting.com ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target ...